Glaukos Corporation (GKOS)

NYQ – Real Time Price. Currency in USD

103.18

-4.57 (-4.24%)

At close: Mar 27, 2026, 4:00 PM EDT

103.18

0.00 (0.00%)

After-hours: Mar 27, 2026, 6:17 PM EDT

Videos

No Data

There is no data to display

Press releases

19.03.2026

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

17.02.2026

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.

28.01.2026

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and re.

13.01.2026

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14.

Glaukos Corporation (GKOS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Glaukos Corporation (GKOS)

Videos

No Data

Press releases

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Videos

No Data

Press releases

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance